{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:00:39Z","timestamp":1794258039641,"version":"4.9.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Exeliom Biociences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72375-y","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:14:19Z","timestamp":1777378459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn\u2019s Disease: a first in human trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7852-0538","authenticated-orcid":false,"given":"Perle","family":"Guarino-Vignon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-7401","authenticated-orcid":false,"given":"Hang-Phuong","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1014-5038","authenticated-orcid":false,"given":"Giovanna","family":"Orianne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Tkacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Brot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolia","family":"Mazzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Sedda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Ruffi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rolhion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hadida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Langella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-1822","authenticated-orcid":false,"given":"Harry","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"72375_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41579-025-01163-0","volume":"23","author":"ID Iliev","year":"2025","unstructured":"Iliev, I. D., Ananthakrishnan, A. N. & Guo, C. J. Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities. Nat. Rev. Microbiol. 23, 509\u2013524 (2025).","journal-title":"Nat. Rev. Microbiol."},{"key":"72375_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","volume":"149","author":"P Moayyedi","year":"2015","unstructured":"Moayyedi, P. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102\u2013109.e6 (2015).","journal-title":"Gastroenterology"},{"key":"72375_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.20046","volume":"321","author":"SP Costello","year":"2019","unstructured":"Costello, S. P. et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321, 156\u2013164 (2019).","journal-title":"JAMA"},{"key":"72375_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2468-1253(21)00400-3","volume":"7","author":"C Haifer","year":"2022","unstructured":"Haifer, C. et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol. Hepatol 7, 141\u2013151 (2022).","journal-title":"Lancet Gastroenterol. Hepatol"},{"key":"72375_CR5","doi-asserted-by":"crossref","unstructured":"Benech, N. & Sokol, H. Targeting the gut microbiota in inflammatory bowel diseases: where are we? Curr. Opin. Microbiol. 74, (2023).","DOI":"10.1016\/j.mib.2023.102319"},{"key":"72375_CR6","doi-asserted-by":"crossref","unstructured":"Sokol, H. et al. Fecal microbiota transplantation to maintain remission in Crohn\u2019s disease: a pilot randomized controlled study. Microbiome 8, (2020).","DOI":"10.1186\/s40168-020-0792-5"},{"key":"72375_CR7","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.1073\/pnas.0804812105","volume":"105","author":"H Sokol","year":"2008","unstructured":"Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. PNAS 105, 16731\u201316736 (2008).","journal-title":"PNAS"},{"key":"72375_CR8","first-page":"978","volume":"20","author":"S Rajca","year":"2014","unstructured":"Rajca, S. et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn\u2019s disease. Inflamm. Bowel Dis. 20, 978\u2013986 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"72375_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1136\/gutjnl-2019-318719","volume":"69","author":"H Sokol","year":"2019","unstructured":"Sokol, H. et al. Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn\u2019s disease. Gut 69, 462\u2013472 (2019).","journal-title":"Gut"},{"key":"72375_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/gutjnl-2015-309184","volume":"65","author":"S Mondot","year":"2016","unstructured":"Mondot, S. et al. Structural robustness of the gut mucosal microbiota is associated with Crohn\u2019s disease remission after surgery. Gut 65, 954\u2013962 (2016).","journal-title":"Gut"},{"key":"72375_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/ecco-jcc\/jjw051","volume":"10","author":"MK Magnusson","year":"2016","unstructured":"Magnusson, M. K. et al. Anti-tnf therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J. Crohns Colitis 10, 943\u2013952 (2016).","journal-title":"J. Crohns Colitis"},{"key":"72375_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/gutjnl-2014-307649","volume":"65","author":"E Qu\u00e9vrain","year":"2016","unstructured":"Qu\u00e9vrain, E. et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn\u2019s disease. Gut 65, 415\u2013425 (2016).","journal-title":"Gut"},{"key":"72375_CR13","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/ibd\/izy182","volume":"24","author":"L Zhou","year":"2018","unstructured":"Zhou, L. et al. Faecalibacterium prausnitzii produces butyrate to maintain th17\/treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. Inflamm. Bowel Dis. 24, 1926\u20131940 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"72375_CR14","doi-asserted-by":"crossref","unstructured":"Touch, S. et al. Human CD4+CD8\u03b1+ Tregs induced by faecalibacterium prausnitzii protect against intestinal inflammation. JCI Insight 7, (2022).","DOI":"10.1172\/jci.insight.154722"},{"key":"72375_CR15","doi-asserted-by":"crossref","unstructured":"Danne, C. et al. Faecalibacterium prausnitzii induces an anti-inflammatory response and a metabolic reprogramming in human monocytes. Gastroenterology 170, 704\u2013720(2025).","DOI":"10.1053\/j.gastro.2025.10.003"},{"key":"72375_CR16","doi-asserted-by":"crossref","unstructured":"Mart\u00edn, R. et al. Faecalibacterium: a bacterial genus with promising human health applications. FEMS Microbiol. Rev. 47, (2023).","DOI":"10.1093\/femsre\/fuad039"},{"key":"72375_CR17","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3389\/fmicb.2017.01226","volume":"8","author":"R Mart\u00edn","year":"2017","unstructured":"Mart\u00edn, R. et al. Functional characterization of novel faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of f. prausnitzii as a next-generation probiotic. Front. Microbiol. 8, 1226 (2017).","journal-title":"Front. Microbiol."},{"key":"72375_CR18","doi-asserted-by":"publisher","first-page":"300416","DOI":"10.3389\/fmicb.2017.01790","volume":"8","author":"L Benevides","year":"2017","unstructured":"Benevides, L. et al. New insights into the diversity of the genus Faecalibacterium. Front. Microbiol. 8, 300416 (2017).","journal-title":"Front. Microbiol."},{"key":"72375_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.crohns.2009.12.003","volume":"4","author":"G Van Assche","year":"2010","unstructured":"Van Assche, G. et al. The second european evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: Definitions and diagnosis. J. Crohns Colitis 4, 7\u201327 (2010).","journal-title":"J. Crohns Colitis"},{"key":"72375_CR20","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"72375_CR21","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res"},{"key":"72375_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst 1, 417\u2013425 (2015).","journal-title":"Cell Syst"},{"key":"72375_CR23","doi-asserted-by":"crossref","unstructured":"Qin, W. et al. Faecalibacterium prausnitzii enhances intestinal IgA response by host-microbe derived inecalcitol in colitis. BMC Med. 23, (2025).","DOI":"10.1186\/s12916-025-04260-2"},{"key":"72375_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/0016-5085(92)91779-4","volume":"102","author":"JL Wallace","year":"1992","unstructured":"Wallace, J. L., Keenan, C. M., Gale, D. & Shoupe, T. S. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 102, 18\u201327 (1992).","journal-title":"Gastroenterology"},{"key":"72375_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/gut.41.4.487","volume":"41","author":"CK Ameho","year":"1997","unstructured":"Ameho, C. K. et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor \u03b1 production in trinitrobenzene sulphonic acid induced colitis. Gut 41, 487 (1997).","journal-title":"Gut"},{"key":"72375_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/19490976.2014.990784","volume":"6","author":"L Laval","year":"2015","unstructured":"Laval, L. et al. Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes 6, 1\u20139 (2015).","journal-title":"Gut Microbes"},{"key":"72375_CR27","doi-asserted-by":"publisher","unstructured":"Krueger, F. et al. FelixKrueger\/TrimGalore: v0.6.10 - add default decompression path (0.6.10). Zenodo https:\/\/doi.org\/10.5281\/ZENODO.7598955 (2023).","DOI":"10.5281\/ZENODO.7598955"},{"key":"72375_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"4 9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nature Methods 49, 357\u2013359 (2012).","journal-title":"Nature Methods"},{"key":"72375_CR29","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41587-023-01688-w","volume":"11 41","author":"A Blanco-M\u00edguez","year":"2023","unstructured":"Blanco-M\u00edguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nature Biotechnology 41, 1633\u20131644 (2023).","journal-title":"Nature Biotechnology"},{"key":"72375_CR30","doi-asserted-by":"crossref","unstructured":"Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with biobakery 3. Elife 10, (2021).","DOI":"10.7554\/eLife.65088"},{"key":"72375_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nm.4102","volume":"22","author":"B Lamas","year":"2016","unstructured":"Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 22, 598\u2013605 (2016).","journal-title":"Nat. Med."},{"key":"72375_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"4 14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nature Methods 4 14, 417\u2013419 (2017). 2017 14.","journal-title":"Nature Methods"},{"key":"72375_CR33","doi-asserted-by":"publisher","first-page":"D942","DOI":"10.1093\/nar\/gkac1071","volume":"51","author":"A Frankish","year":"2023","unstructured":"Frankish, A. et al. GENCODE: reference annotation for the human and mouse genomes in 2023. Nucleic Acids Res 51, D942\u2013D949 (2023).","journal-title":"Nucleic Acids Res"},{"key":"72375_CR34","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.2","volume":"1521 4","author":"C Soneson","year":"2016","unstructured":"Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Research 2015 4, 1521 (2016).","journal-title":"F1000Research"},{"key":"72375_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 1\u201321 (2014).","journal-title":"Genome Biol"},{"key":"72375_CR36","doi-asserted-by":"publisher","first-page":"D679","DOI":"10.1093\/nar\/gkad960","volume":"52","author":"A Agrawal","year":"2024","unstructured":"Agrawal, A. et al. WikiPathways 2024: next generation pathway database. Nucleic Acids Res 52, D679\u2013D689 (2024).","journal-title":"Nucleic Acids Res"},{"key":"72375_CR37","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic, M. et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res 52, D672\u2013D678 (2024).","journal-title":"Nucleic Acids Res"},{"key":"72375_CR38","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"72375_CR39","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. bioRxiv 060012 (2021) https:\/\/doi.org\/10.1101\/060012.","DOI":"10.1101\/060012"},{"key":"72375_CR40","doi-asserted-by":"publisher","unstructured":"Wickham, H. Ggplot2. (Springer International Publishing, Cham, 2016). https:\/\/doi.org\/10.1007\/978-3-319-24277-4.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"72375_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J 17, 10\u201312 (2011).","journal-title":"EMBnet. J"},{"key":"72375_CR42","doi-asserted-by":"publisher","unstructured":"Nickols, W. A. et al. MaAsLin 3: Refining and extending generalized multivariable linear models for meta-omic association discovery. bioRxiv 2024.12.13.628459 (2024) https:\/\/doi.org\/10.1101\/2024.12.13.628459.","DOI":"10.1101\/2024.12.13.628459"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72375-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72375-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72375-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:14:18Z","timestamp":1783059258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72375-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72375"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72375-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.S. discloses receiving lecture fees, serving on boards, or providing consultancy for Carenity, AbbVie, Astellas, Danone, Ferring, Mayoly Spindler, MSD, Novartis, Roche, Tillots, Enterome, BiomX, Takeda, and Biocodex. Additionally, H.S. holds stocks in Enterome and is a co-founder of Exeliom Biosciences. The findings presented in this manuscript were not shared with these companies. E.M, D.S., P.R., and B.H. are employees of Exeliom Biosciences. E.L. department received grants from Abbvie, Takeda, Janssen, Pfizer, Fresenius-Kabi, Celltrion, EG pharma, Sandoz, Falk. E.L. received lecture fees, serving on boards, or providing consultancy for Abbvie, Takeda, Ferring, Pfizer, Janssen, Lilly, Galapagos, Celltrion, Arena, BMS, Falk, Biokuris, Fresenius-Kabi, Thabor. G.D. reports research grants from Abbvie, Alimentiv, BMS, J&J, Pfizer, Takeda; Consulting fees from Abbvie, Agomab, Alimentiv, AstraZeneca, AMT, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Galapagos, Index Pharmaceuticals, Kaleido, Glaxo Smith Kline, Pfizer, Immunic, Johnson and Johnson, Mirador, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity, Protagonist, Spyre, Ventyx; speaking fees from Abbvie, Arena, Boehringer Ingelheim, Celltrion, Galapagos, Gilead, Eli Lilly, Pfizer, BMS, Takeda. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5823"}}